- Home
- WFC vs NVS Comparison
WFC vs NVS Comparison
Compare WFC & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WFC | NVS |
|---|---|---|
| Founded | 1852 | 1895 |
| Country | United States | Switzerland |
| Employees | N/A | 75267 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.6B | 310.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | WFC | NVS |
|---|---|---|
| Price | $74.26 | $153.54 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 16 | 4 |
| Target Price | $97.37 | ★ $118.00 |
| AVG Volume (30 Days) | ★ 14.6M | 2.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.39% | 2.01% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.46 | $2.56 |
| Revenue Next Year | $4.55 | $4.91 |
| P/E Ratio | ★ $14.15 | $23.13 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $58.42 | $97.72 |
| 52 Week High | $97.76 | $170.46 |
Technical Indicators
Market Signals| Indicator | WFC | NVS |
|---|---|---|
| Relative Strength Index (RSI) | 25.55 | 39.98 |
| Support Level | $71.95 | $113.19 |
| Resistance Level | $78.37 | $158.80 |
| Average True Range (ATR) | 2.43 | 2.48 |
| MACD | -0.85 | -2.06 |
| Stochastic Oscillator | 1.57 | 2.05 |
Price Performance
Historical ComparisonAbout WFC Wells Fargo & Company
Wells Fargo is one of the largest banks in the United States, with approximately $2.1 trillion in balance-sheet assets. The company has four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the US market.
About NVS Novartis AG
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.